文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌自适应SBRT中HyperSight™成像的纵向组织勾画分析

Advanced HyperSight™ imaging for patients with adaptive SBRT of prostate cancer: a longitudinal analysis of tissue demarcation.
PubMed 文献 · Radiat Oncol · 2025-10-16

本研究纳入26例接受Ethos®直线加速器自适应SBRT的前列腺癌患者,比较新型HyperSight™-CBCT(hCBCT)与计划CT的纵向图像质量及前列腺、精囊腺、直肠壁的轮廓锐度。结果显示hCBCT提供与pCT相当的组织可视化,但轮廓锐度和勾画信心随分次下降,且与评估时间延长相关。

要点

  • hCBCT在前列腺癌自适应SBRT中提供与pCT相当的组织可视化。
  • 前列腺和精囊腺轮廓锐度及勾画信心随治疗分次显著下降。
  • 观察者经验影响评分,住院医师评分低于经验丰富的放疗医生。

核心结论

  • hCBCT为前列腺癌自适应SBRT提供高质量成像,组织可视化与pCT相当。
  • 纵向hCBCT可检测到轮廓锐度随分次下降,可能与治疗引起的组织改变有关并影响ART工作流程。

研究设计与样本

  • 体模研究评估pCT和hCBCT图像质量;患者分析纳入全部156次扫描(pCT及每次分次hCBCT)。
  • 纵向评估图像质量、前列腺/精囊腺/直肠壁轮廓锐度及勾画信心,并记录ART参数所需时间。

主要发现

  • hCBCT在体模和患者分析中均显示稳健的图像质量参数。
  • 观察者间一致性为中等,住院医师评分低于经验丰富的放疗医生(p < 0.001)。
  • pCT与首次hCBCT之间前列腺和精囊腺轮廓锐度无显著差异,但轮廓锐度评分随治疗分次下降。
  • 后期分次中前列腺和精囊腺勾画信心显著降低(每项padj<0.05),且与评估时间延长显著相关(padj≤0.05)。
  • 前列腺和精囊腺邻近脂肪组织的CT衰减值随分次显著增加(padj<0.05)。

关键数值与推荐

  • 定量指标包括前列腺和精囊腺邻近脂肪的CT值变化。
  • 统计方法采用Friedman检验(Bonferroni校正)、Spearman相关和组内相关系数(ICC)。

临床怎么用

  • hCBCT可用于前列腺癌自适应SBRT的日常图像引导和ART工作流程。
  • 需关注随分次增加的前列腺和精囊腺轮廓锐度及勾画信心下降,可能需额外评估时间。
  • 勾画评分受观察者经验影响,应重视培训与质量控制。

局限性

  • 观察者经验可能影响对观察效果的评分。
  • 样本量有限(26例患者,156次扫描),结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cone-beam computed tomography (CBCT)-based adaptive radiotherapy (ART) at the Ethos® linear accelerator (eLinac) allows for daily anatomical and dosimetric adjustments and relies on robust image quality. This study evaluated the longitudinal image quality of the novel HyperSightTM-CBCT (hCBCT) compared to planning CT (pCT), using phantoms and data of prostate cancer patients undergoing adaptive stereotactic body radiotherapy (SBRT). Building on this, the longitudinal contour sharpness of the organs in fractional hCBCT and their usability for ART workflow across fractions was evaluated. METHODS: Between December 2023 and May 2024, 26 prostate cancer patients receiving ART at the eLinac with hCBCT technology were enrolled. Phantom studies assessed pCT and hCBCT image quality. Patient based analyses of all 156 imaging scans (pCT and each of the fractional hCBCT) analyzed, longitudinally examined firstly image quality, secondly contour sharpness of prostate, seminal vesicles, and rectal wall, and thirdly confidence to delineate the structures for the ART workflow. Time required for the ART based parameters were recorded. Quantitative metrics included CT number changes in the fat adjacent to the prostate and seminal vesicles. Friedman’s test with Bonferroni correction, Spearman and Intraclass Correlation Coefficient (ICC) were used for statistics. RESULTS: hCBCT scans showed robust image quality parameters in the phantom and patient based analysis across fractions. Inter-observer agreement was moderate, with lower rating score for resident compared to the experienced radiation oncologist (p < 0.001). Patient based analysis showed no significant differences of the contour sharpness of the prostate and seminal vesicles between pCT and initial hCBCT scan, but contour sharpness ratings declined across treatment fractions. Confidence for the delineation of prostate and seminal vesicles during ART was significantly decreased at later fractions (each padj<0.05) and this correlated significantly with longer assessment times (padj≤0.05). The CT attenuation of the fat tissue adjacent to the prostate and seminal vesicles significantly increased across the fractions (padj<0.05). CONCLUSIONS: High-quality imaging for adaptive SBRT in prostate cancer is provided by hCBCT, which offers equivalent tissue visualization compared to pCT. Fraction-dependent decreases in contour sharpness can be detected using longitudinal hCBCT imaging. These decreases are likely related to treatment-induced tissue changes and may impact ART workflow. The rating of the observed effects may potentially be influenced by the observer’s experience.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schmidt R, Nguyen T, Bicu AS, et al. Advanced HyperSight™ imaging for patients with adaptive SBRT of prostate cancer: a longitudinal analysis of tissue demarcation. Radiat Oncol. 2025. PMID: 41094662. doi:10.1186/s13014-025-02730-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。